Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720174 · ClinicalTrials.gov registry record · Phase 1
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 study of Adult Angiosarcoma and Adult Epithelioid Sarcoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 13
- Study locations
NCT00720174 is a Phase 1 study of Adult Angiosarcoma and Adult Epithelioid Sarcoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. The trial reports 13 study locations across 6 states.
The verdict
NCT00720174, a Phase 1 study of Adult Angiosarcoma and Adult Epithelioid Sarcoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 13
- Study locations
Study Summary
This phase I trial is studying the side effects and best dose of cixutumumab given together with doxorubicin hydrochloride and to see how well they work in treating patients with unresectable, locally advanced, or metastatic soft tissue sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibody cixutumumab together with doxorubicin hydrochloride may kill more tumor cells.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Doxorubicin Hydrochloride
- BIOLOGICAL Cixutumumab
Study Locations (13)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
- Decatur Memorial Hospital - Decatur
- NorthShore University HealthSystem-Evanston Hospital - Evanston
- Ingalls Memorial Hospital - Harvey
- Joliet Oncology-Hematology Associates Limited - Joliet
- Loyola University Medical Center - Maywood
- Illinois CancerCare-Peoria - Peoria
- Central Illinois Hematology Oncology Center - Springfield
Indiana
- Fort Wayne Medical Oncology and Hematology Inc-Parkview - Fort Wayne
Maryland
- University of Maryland/Greenebaum Cancer Center - Baltimore
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Missouri
- Mercy Hospital Saint Louis - St Louis
Wisconsin
- Froedtert and the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720174
The ClinicalTrials.gov registry entry for NCT00720174 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Adult Angiosarcoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00720174 reports 13 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Indiana, Maryland.
Frequently Asked Questions
What is clinical trial NCT00720174 about?
NCT00720174 is a clinical study titled "Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma". This phase I trial is studying the side effects and best dose of cixutumumab given together with doxorubicin hydrochloride and to see how well they work in treating patients with unresectable, locally advanced, or metastatic soft tissue sarcoma. Monoclonal antibodies, such as cixutumumab, can block ...
What is the current status of trial NCT00720174?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-06.
What conditions does trial NCT00720174 study?
This clinical trial studies the following conditions: Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Desmoplastic Small Round Cell Tumor.
What interventions are being tested in trial NCT00720174?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Doxorubicin Hydrochloride (DRUG), Cixutumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00720174?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00720174 being conducted?
This trial has 13 study locations across Illinois, Indiana, Maryland, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Angiosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.